BlackRock snagged 5,763,606 shares of ATYR on 6/30 for a 6.5% stake in the company. BlackRock is a long-term investment firm with a low turnover rate, which essentially locks up more of ATYR’s float in the hands of folks who aren’t likely to sell on the back side of aTyr Pharma’s upcoming catalyst should their Phase 3 trial of Efzofitimod prove successful.
Updated short interest percentages and the updated list of institutional investors is expected in the coming days. The setup looks promising!
👉 https://investors.atyrpharma.com/node/16566/html